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none has detectable bcr/abl transcripts in blood or marrow. One
patient (CML-CP3) with cytogenetic relapse at D  118 had a
fourth remission after withdrawal of immunosuppression and con-
tinued imatinib but developed hematological relapse at D  429.
Conclusions: We conclude that imatinib therapy can be safely
prescribed early after myeloablative allogeneic HCT at a dose-
intensity comparable to that used in general oncology. Preliminary
efﬁcacy data are encouraging and worthy of further study (Table1).
Table 1. Patient Characteristics and Outcomes
ALL
(n  12)
CML
(n  6)
Pretransplant characteristics
Disease phase, N CR1 10, CR2 2
AP 2, CP2 2, CP3
2
Patients with MRD1 present, N 9 6
Median age, years (range) 36 (5–49) 45 (36–62)
Related donor, unrelated
donor, N 5, 7 2, 4
Peripheral blood, marrow,
cord blood, N 8, 3, 1 4, 1, 0
Posttransplant outcomes
Imatinib therapy start day,
median (range) 28 (24–39) 29 (25–36)
Imatinib therapy, days of,
median (range) 183 (3–381) 243 (89–353)
Average daily imatinib doses,
milligrams
<Day 90, median (range) 400 (2122–400) 400 (novariance)
>Day 90, median (range) 400 (2502–550) 400 (novariance)
Survival, days, median (range) 214 (27–600) 511 (130–627)
Molecular
remission/completed
therapy, N/N 4/4 3/4
Molecular remission/continue
Imatinib, N/N 8/8 2/2
1MRD  minimal residual leukemia by cytogenetic and/or molec-
ular methods.
2Two children did not receive 400 mg per day but received close to
340 mg/m2/day.
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DIFFERENCES IN THE PHENOTYPE AND IN VIVO ANTI-TUMOR ACTIV-
ITY OF WT1 SPECIFIC AND EBV-SPECIFIC T-CELLS GENERATED IN
VITRO FOR ADOPTIVE IMMUNOTHERAPY
Doubrovina, E.1, Dupont, J.1, Kanaeva, E.1, Doubrovin, M.1,
O’Reilly, R.1 Memorial Sloan-Kettering Cancer Center, New York, NY.
Our studies in SCIDmouse/human tumor xenograft models have
demonstrated that T cells sensitized with autologous EBV BLCL
in vitro will, following intravenous transfer into mice bearing
tumors varying in HLA type and expression of EBV antigens,
selectively accumulate in EBV tumors co-expressing the T cell’s
HLA restricting allele, and will proliferate and persist in these
tumors through there complete regression. In contrast while T
cells sensitized against WT1 peptides presented by peptide-loaded
autologous DCs or EBV BLCL in vitro also exhibit HLA-re-
stricted accumulation in WT1 tumor xenografts and induce
signiﬁcant inhibition of tumor growth, they persist only for periods
of 8 days following adoptive transfer. By day 15, the T cells were
no longer detectable in the tumors, following which the regrowth
of WT1 expressing tumors was again observed. Accordingly, we
compared T cells sensitized in vitro with autologous EBV BLCL
alone or with EBV BLCL loaded either with the pool of overlap-
ping 15-mers spanning over WT1 sequence or transduced to
express WT1. Antigen-speciﬁc T cells were then characterized as
to their speciﬁcity and HLA restriction. Antigen-reactive T cells
were then isolated on the basis of IFN production in response to
secondary restimulation with APCs bearing targeted peptides and
the appropriate restricting HLA alleles and evaluated for their
phenotype and tumor-speciﬁc activity. Both CD4 and CD8
EBV-speciﬁc T cells exhibited HLA-restricted lysis of EBV
tumor cells while the CD8 WT1 speciﬁc T cells consistently
lizedWT1 tumors bearing HLA restricting HLA class I allele. The
CD4 T cells were not cytotoxic. The WT1-speciﬁc and EBV-
speciﬁc CD4 T cells did not differ in phenotype. However, while
CD8 T cells speciﬁc for EBV expressed an effector memory
phenotype (CD3 CD8 CCR7 CD45RA CD45RO
CD62L CD25), the WT1 speciﬁc CD8 T cells were predom-
inantly of a central memory type (CD3 CD8 CCR7
CD45RA CD45RO CD62L CD25). These studies suggest
that T cells generated against WT1 in vitro may be relatively
deﬁcient in effector memory T cells required to induce complete
tumor regression in vivo.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR MALIG-
NANCIES USING UMBILICAL CORD BLOOD UNITS (UCB) THAT WERE
NOT RED BLOOD CELL DEPLETED
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StemCyte International Cord Blood Center, Arcadia, CA; 2. City of
Hope National Medical Center, Duarte, CA; 3. University of Arizona
Medical Center, Tuscon, AZ; 4. Mount Elizabeth Hospital, Singapore,
Singapore; 5. Chung Gung Memorial Hospital, Linko, Taiwan; 6.
UCLA Medical Center, Los Angeles, CA.
Cell dosage is a limiting factor for UCB HSCT, especially for adult
patients. Most UCB banks practice red cell depletion (RCD) tech-
niques to save storage space, which incur signiﬁcant nucleated cell loss
after processing. One method of minimizing cell loss and still reduce
volume after processing is to deplete plasma (PD), but not the red
blood cells. Not washing UCB after thawing also minimizes cell loss.
A large, racially diverse PD UCB inventory of 18,000 units is now
available on stem cell registries. A retrospective analysis was per-
formed on 70 patients with malignancies without prior HSCT who
were transplanted during remission with PD UCB. There were 28
ALL, 16 AML, 8 CML, 7MDS/RA/RAEB, 3 JMML, and 8 others.
Of the ALL/AML/CML cases with available information, there were
19 1CR/CP, 10 2CR, and 9 3CR/CP. The median age of patients was
5.8 years old (range 0.5–54); median weight 23 kg (range 5–84); male
63%. Transplant characteristics indicated a median # HLA ABDR
matches of 5.0 (11-6/6; 23-5/6; 27-4/6; 8-/6; 1-/6;) median pre-freeze
TNC dose 6.4 107/kg; median post-thaw TNC dose as reported by
TC 5.3  107/kg; median pre-freeze CD34 dose 2.5  105/kg;
transplants outside of U.S. 24%; double unit transplant 14%; non-
myeloablative 7%. Forty-seven percent of the transplanted UCBwere
washed post-thaw (W), 33% were infused without post-thaw wash
(NW), with 20% of the units without available post-thaw data. Me-
dian time to engraftment for ANC 500 (n  66), platelet 20K (n 
52), and 50K (n 50) were 24 days (range 7–49 days), 53 days (range
15–94 days), and 63 days (range 37–132 days), respectively. Median
time to engraftment for W versus NW were 28 versus 23 days for
ANC500, and 55 versus 49 days for platelet 20K, respectively. The
unadjusted cumulative incidence (C.I.) of ANC500 and platelet 20K
and 50K engraftments are 93  3%, 76  6%, and 75  6%,
respectively. The incidence of reported grade II-IV and III-IV acute
GVHD were 37% and 20%, respectively. Twelve percent developed
limited chronic GVHD and 15% developed extensive chronic
GVHD. With a median follow-up of 282 days (range 50–1263 days),
the Kaplan-Meier estimates of 1-year TRM, OS and relapse-free
survival were 20  6%, 67  6%, and 59  7%, respectively. These
results demonstrate that HSCT using unrelated PD UCB can be
performed safely and effectively in patients with malignancies, and
post-thaw wash may not be necessary.
249
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